Shikari® (S-ATB) Anti-Bevacizumab ELISA w/confirmation
BEV-QNS-AA
Enzyme immunoassay for the quantitative determination of antibodies to Bevacizumab (Avastin®) in serum and plasma with confirmation.
This kit has been especially developed for the quantitative antibodies to Bevacizumab in serum and plasma samples.
Bevacizumab (Avastin®) was associated to the development of anti-bevacizumab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Avastin®.This might lead to severe complications. This kit can be efficiently used for monitoring anti- bevacizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-bevacizumab antibodies.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system.
Research Use Only (RUO)
For technical inquiry, IFU and other relevant documents please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 20 |
| Total Time (min) | 140 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 7,5 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| Safety Data Sheet (SDS) | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Formica, María Lina, et al. "Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody–Bevacizumab–and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies." Materials Science and Engineering: C 119 (2020): 111398. | Visit Link | |
| Luis de Redín, Inés, et al. "In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer." Drug Delivery and Translational Research 10 (2020): 635-645. | Visit Link | |
| Llabot, Juan M., et al. "In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV)." Journal of Drug Delivery Science and Technology 52 (2019) | Visit Link | |
| Gregoritza, Manuel, et al. "Fabrication of antibody-loaded microgels using microfluidics and thiol-ene photoclick chemistry." European Journal of Pharmaceutics and Biopharmaceutics 127 (2018): 194-203. | Visit Link | |
| de Redín, Inés Luis, et al. "Human serum albumin nanoparticles for ocular delivery of bevacizumab." International Journal of Pharmaceutics 541.1-2 (2018): 214-223. | Visit Link | |
| Gojo, Johannes, et al. "Pharmacokinetics of bevacizumab in three patients under the age of 3 years with CNS malignancies." Drugs in R&D 17 (2017): 469-474. | Visit Link | |
| Gregoritza, Manuel, et al. "Controlled antibody release from degradable Thermoresponsive hydrogels cross-linked by Diels–Alder chemistry." Biomacromolecules 18.8 (2017): 2410-2418. | Visit Link | |
| Chen, Lei, et al. "Efficient production of a bioactive bevacizumab monoclonal antibody using the 2A self-cleavage peptide in transgenic rice callus." Frontiers in plant science 7 (2016): 1156. | Visit Link | |
| Van Bergen, Tine, et al. "Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery." Acta Ophthalmologica 93.7 (2015): 667-678. | Visit Link | |
| Akbulut, Hakan, et al. "The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study." (2018): e15553-e15553. | Visit Link | |
| Akbulut, H., et al. "The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC)." Annals of Oncology 27 (2016): vi537. | Visit Link | |
| Peña Cabia, Silvia. "Evaluación de la relación exposición-respuesta de bevacizumab y de cetuximab en cáncer colorrectal metastásico y de cetuximab en cáncer de cabeza y cuello." (2022). | Visit Link | |
| Legeron, Rachel. La spectrométrie de masse appliquée à la quantification absolue des anticorps monoclonaux thérapeutiques en milieu plasmatique pour la réalisation d'études pharmacocinétiques-pharmacodynamiques. Diss. Université de Bordeaux, 2015. | Visit Link | |
| Uğurlu, Nagihan. "Nanoteknoloji Bazlı İlaç Taşıma Sistemlerinin Göze İlaç Uygulamalarında, Transkleral Geçiş Üzerine Etkisinin Değerlendirilmesi." (2013). | Visit Link | |
| Ramos Membrive, Rocío. Radiomarcaje y biodistribución mediante SPECT/CT de nanopartículas de seroalbúmina humana con bevacizumab. Diss. Universidad de Navarra, 2020. | Visit Link | |
| Paul, B. Yu, and Marcelo Dicarli. "Imaging probe for angiogenic activity in pulmonary arterial hypertension." U.S. Patent Application No. 15/770,994. | Visit Link | |
| The plant source recombinant humanized shellfish of a kind of optimization cuts down preparation method and the medical applications of monoclonal antibody, 于为常陈磊 | Visit Link | |
| Pangua, Cristina, et al. "Mucus-penetrating and permeation enhancer albumin-based nanoparticles for oral delivery of macromolecules: Application to bevacizumab." Drug Delivery and Translational Research 14.5 (2024): 1189-1205. | Visit Link | |
| Akay Hacan, Büşra. "Rutin tedavi olarak bevacizumab kullanılan metastatik kolorektal kenserli kolorektal kanserli hastalarda tedavi etkinliğinin belirlenmesinde biyobelirteçlerin rolü." | Visit Link | |
| Pangua, Cristina, et al. "Enhancing bevacizumab efficacy in a colorectal tumor mice model using dextran-coated albumin nanoparticles." Drug Delivery and Translational Research (2024): 1-18. | Download | |
| Pangua, Cristina, et al. "Evaluation of nanoencapsulated bevacizumab combined with paclitaxel in a colorectal cancer xenograft model." Drug Delivery and Translational Research (2025): 1-13. | Download |
